Is there any news whether Belumosudil will be included in medical insurance coverage by 2026?

Belumosudil mesylate tablets (Belumosudil) is a kinase inhibitor used to treat chronic graft-versus-host disease (GVHD). Besudil provides a new treatment option, especially for patients who have poor response to traditional glucocorticoids or other systemic treatments. Since Besudil was launched on the Chinese market, it has quickly become one of the key drugs for the treatment of chronic GVHD. Both patients and medical practitioners are concerned about whether it can be more widely covered by medical insurance to reduce the burden of treatment.

Currently, besudil mesylate has been launched in the domestic market and has been included in the medical insurance catalog, especially for patients with chronic GVHD who have insufficient response to glucocorticoids or other treatments. The inclusion of medical insurance undoubtedly brings great convenience to patients, especially for chronic GVHD, a relatively rare and difficult-to-treat disease, whose treatment costs are often expensive. Therefore, the medical insurance coverage of Besudil provides necessary financial support for the majority of patients.

As to whetherthere will be further expansion of medical insurance in 2026, although there is currently no clear official announcement, it can be reasonably expected that as Besudil continues to accumulate experience and efficacy data in clinical treatment, more patient groups may be included in the medical insurance coverage in the future. Generally speaking, whether a drug can be included in medical insurance is mainly based on multiple factors such as its clinical effect, market demand, and economic impact on the public health system. In the future, with the increasing demand for chronic GVHD treatment and the positive role of besudil in treatment, it is possible that more clinical research and data support will promote its expansion in medical insurance coverage.

Globally, as a new type of drug, besudil has been increasingly recognized for its targeted and unique treatment. As the understanding of chronic GVHD continues to deepen at home and abroad, besudil's status will become increasingly important.

Reference: https://www.drugs.com/pro/rezurock.html